Clinical Benefits of Hepatic Arterial Infusion Chemotherapy for Advanced Hepatocellular Carcinoma

Recent success of systemic therapeutic agents, including combination immunotherapy, could promote a change in the treatment strategy in patients with advanced hepatocellular carcinoma (HCC). Although hepatic arterial infusion chemotherapy (HAIC) is a treatment option for advanced HCC in Japan, it is not recommended by other guidelines. We discuss the clinical benefits of HAIC compared to sorafenib. The clinical benefits of HAIC are as follows: (1) even a patient with Child-Pugh B HCC (7 or 8 points) is a candidate for HAIC (2) Child-Pugh scores barely decline with the use of HAIC compared with sorafenib (3) HAIC is highly effective in patients with vascular invasion compared with sorafenib; and (4) survival in patients receiving HAIC may not be associated with skeletal muscle volume. In contrast, the disadvantages are problems related with the reservoir system. HAIC has clinical benefits in a subpopulation of patients without extrahepatic metastasis with Child-Pugh A HCC and vascular invasion (especially primary branch invasion or main portal vein invasion) or with Child-Pugh B HCC.

Automated summary

The study discussed the clinical benefits of hepatic arterial infusion chemotherapy (HAIC) compared to sorafenib in treating patients with hepatocellular carcinoma (HCC), including the ability to treat a wider range of patients, minimal impact on Child-Pugh scores, and higher efficacy in patients with vascular invasion.